|
|
Article: Zonagen Loses ED Drug Partner, Submits One-Year Study Results.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Zonagen Inc. reported a mixed bag of news regarding its phentolamine-based technologies to treat sexual dysfunction.
The Woodlands, Texas-based firm said it agreed to split with Schering-Plough Corp., terminating worldwide licensing agreements covering technologies including Vasomax, Zonagen's oral therapy to treat erectile dysfunction.
"We felt it was coming," Zonagen President and CEO Joseph Podolski told BioWorld Today. "It's certainly not a good thing, but in this case, given how this market is evolving, it gives us the opportunity to shop this product again and also gives us the opportunity to shop our second and third ...